Vivos Inc RDGL

$0.05 0.00 (-8.03%)

Valuation

Market cap
24,599,000
Revenue TTM
$70,000
Net income TTM
$-3,070,000
PE ratio
0.00
Forward PE
—
Profit margin
-4,385.71%
Debt to equity
0.00

Trading

Volume
663,500
Avg volume
922,462
Day's range
$0.04 – $0.05
Shares out
493,964,000
Stochastic %K
25%
Beta
-0.55
Analysts
Strong Buy
Price target
—

Price

Company profile

Vivos Inc., a radiation oncology medical device company, engages in the development of yttrium-90-based precision radionuclide therapy devices for the treatment of non-resectable tumors in the United States. The company develops RadioGel, which is an injectable particle-gel for Precision Radionuclide Therapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in...

Show more

Vivos Inc., a radiation oncology medical device company, engages in the development of yttrium-90-based precision radionuclide therapy devices for the treatment of non-resectable tumors in the United States. The company develops RadioGel, which is an injectable particle-gel for Precision Radionuclide Therapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. It is also developing PLGA-g-PEG polymers; PrecisionGel, a hydrogel polymer platform for delivering active pharmaceutical ingredients and therapeutic agents; Duncan Chiller, a general laboratory equipment for non-water localized chilling; and other products under the Alpha-Gel, Beta-Gel, Gamma-Gel, and Peltier Chiller brands. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Kennewick, Washington.

Industry
Medical Devices
Sector
Healthcare
Phone
509 222 2222
Website
https://radiogel.com
Address
1030 N Center Parkway, Suite N288, Kennewick, United States

Latest news

No headlines yet.